Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Dr. Avrum Spira in the clinic
If Allegro Diagnostics’ clinical trials go as planned, the Maynard, Mass.-based company will be on its way to commercializing a test to detect the "canary in the coal mine" of the planet’s deadliest cancer: Early-stage lung cancer.
With a patented molecular diagnostic assay, Allegro co-founder and Boston University associate professor Avrum Spira has garnered over $3.5 million in funding from the National Institutes of Health and $8.9 million from investors.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Allegro Diagnostics named Duncan Whitney to be its new vice president of research and development.
Whitney’s resumé includes stints at Exact Sciences Corp. (NSDQ:EXAS), U.S. Genomics Inc. and Progenika Inc.
MassDevice Network
@MassDevice
LinkedIn
YouTube